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Background. Uncertainty exists about the current risk of hepatitis A virus infection in nonimmune travelers
to destinations with high or intermediate risk of transmission. We analyzed recent epidemiological data on imported
hepatitis A to determine region-specific attack rates and incidences.
Methods. Surveillance data on hepatitis A virus infections diagnosed during 1988–2004 were evaluated on the
basis of notification by laboratories, additional reports of physicians, and traveler’s statistics. This study focuses
on international travelers with hepatitis A virus infection detected after their return to Switzerland.
Results. The rate of imported hepatitis A virus infections decreased 75% from 1988 to 2004 and accounted
overall for 42% of all hepatitis A cases reported in Switzerland. The actual incidence of hepatitis A in travelers to
countries of high or intermediate risk of transmission was 3.0–11.0 per 100,000 person-months abroad for all
travelers and 6.0–28.0 per 100,000 for those presumed to be nonimmune. The actual proportion of those visiting
friends and relatives among patients with hepatitis A has increased to 28.2%, with children aged 0–14 years
predominating. Reductions in the incidence by hepatitis A vaccination were estimated to vary between 35.0% and
61.8% for different destinations.
Conclusions. The risk of hepatitis A virus infections has decreased by a factor of 10–50-fold over time, compared
with findings from older studies. The risk, however, remains very considerable at many destinations, including
frequently visited places, such as Mexico. Children of immigrants are a high-risk population. Strategies are needed
to reach those at highest risk.
Hepatitis A virus (HAV) infection traditionally has been
considered the most frequent vaccine-preventable in-
fection among nonimmune travelers who visited de-
veloping countries [1]. More recently it has been dem-
onstrated that this first rank belongs to influenza [2].
Additionally, a recent Canadian survey suggested that
the monthly incidence of 3 cases per 1000 travelers,
derived from a follow-up study 2 decades ago, now
might be an overestimation. However, the authors con-
cluded that the 10-fold-lower incidence they extrapo-
lated may have been influenced by a large proportion
of travelers to comparatively low-risk destinations in
the Caribbean [3]. This prompted us to analyze HAV
infections imported to Switzerland from 1988 to 2004
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and to compare the results with the first studies con-
ducted in the 1970s [4, 5]. For the past 10 years, more
than one-third of all cases of hepatitis A diagnosed in
Switzerland have been acquired abroad. It is thus rel-
evant for public health and for individual travelers’
health to estimate region-specific incidences.
METHODS
Study population. Acute viral hepatitis A was a no-
tifiable disease in Switzerland throughout the study pe-
riod from 1988 to 2004 (and before). All laboratories
are requested to report positive results of anti-HAV IgM
antibody measurement to the authorities. Additionally,
the physician in charge of the patient is requested to
submit detailed information about the patient’s de-
mographic characteristics, clinical assessment and
course of the disease, vaccination status, potential places
of exposure, and potential secondary spread. Mainly
symptomatic infections were documented unless there
were other reasons for serological testing reported (e.g.,
screening of children following suspected exposure).
On the basis of the proportion of missing laboratory
or physician reports, it is estimated that ∼80% of HAV
infections are reported.
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To compare data over time more robustly, the study period
was grouped into three 5- to 6-year intervals. Also, destination-
specific information was compared with data collected from
1971 to 1981 [4, 5]. Patients’ ages, initially analyzed in eighteen
5-year categories, is here summarized in five 15-year groups.
Traveler statistics collected by the Swiss Federal Office of
Statistics for 1988 to 2002 [6] were used as denominator to
calculate the attack rates and incidences; the 2003 and 2004
data had to be estimated, because travelers’ statistics were not
yet available. Information sources for travel statistics included
national tourist offices, national offices of statistics, embassies,
and the World Tourism Organization to collate data of arrivals
of Swiss residents to various countries or regions worldwide
(11 day of stay). Missing travel statistics for a few years had
to be estimated when countries failed to provide data, such as
the former Yugoslavia during its breakup. Travel regions were
coded as described by the United Nations Development Agency
[7]. Both the attack rate per trip to a destination and the
incidence per month of stay abroad are described. The mean
duration of stay at the destination and the proportion of those
already immune against hepatitis A were derived from Swiss
data from airport surveys [8, 9] and unpublished estimates by
experts. The mean travel duration provided consistent infor-
mation when compared with a cohort of Swiss travelers to
tropical and subtropical destinations [2].
Statistical analysis. Data were analyzed using Stata statis-
tical software, version 8.2 (Stata). The crude attack rates per
100,000 travelers (with 95% CIs) were calculated by using the
number of reported HAV cases as numerator and the estimated
total number of travelers to a specific region in the defined
time range from the travel database as denominator. To obtain
incidences per month for nonimmune travelers, average du-
ration of stay and the proportion of those with previous im-
munity were taken into account.
Differences in proportions of the demographic and clinical
variables were compared by 2-tailed Pearson’s x2 square and
by Fisher’s exact test. Trends across time groups were evaluated
by the nonparametric test for trend developed by Cuzick [10],
an extension of the Wilcoxon rank sum test. The level of sta-
tistical significance was set at !.05. To determine independent
risk factors associated with travel history and with exposure to
an infected person, respectively, adjusted ORs were calculated
by stepwise logistic regression. The incidence data of the pre-
vaccination era (1971–1993) were approximated by potential
functions ( , where y is region-specific incidence, a isbyp ax
slope of the curve, x is time [e.g., year of reporting], and b is
region-specific factor) and were extrapolated to the recent time
period (2000–2004) to achieve an incidence estimate account-
ing for factors others than HAV vaccination, such as changes
in hygienic conditions at the destination. The immunity-related
reduction in incidence was then estimated by calculating the
proportion of the difference between the region-specific ex-
trapolated incidence and the observed incidence in relation to
the extrapolated one.
RESULTS
Laboratory reports were submitted for 7751 HAV infections
for the total study period, and from these, 6592 physician’s
reports (85.0%) could be assessed for detailed information.
Among these, 2784 (42.2%) reported a travel history, 2581
(92.7% of the imported cases) provided destination-specific
data, and another 2631 (39.9%) were clearly indicated to have
acquired HAV infection in Switzerland. For the remaining 1177
cases (17.9%), no presumed site of infection was noted.
Although in the beginning of the study period up to 942
HAV infections were recorded per year, a substantial decrease
in the total annual number of cases was observed. Since 2001,
less than 200 cases per year were reported, which corresponds
to an annual incidence of 2.5 cases of HAV infection per
100,000 residents. The ratio of male patients to female patients
was 1.7 and did not vary significantly between groups with or
without physician reports nor between infections imported or
acquired in Switzerland (table 1). Recent travel was the major
exposure risk reported, and it accounted on average for 42.2%
(range, 33.3%–58.8%) of all HAV infections (mean, 164 cases
per year; range, 51–277 cases per year). In the travel-associated
subgroup, a contact with contaminated food (10.4%) and ex-
posure to infected contacts (11.9%) were reported most
frequently.
A total of 281 HAV infections (10.7%) acquired in Switzer-
land were reported in patients with foreign nationality, whereas
701 cases (25.2%) were documented in the travel-associated
group. Five hundred seventy-three (82%) of these travelers were
classified as having visited friends and relatives. They reported
a travel history to their country of origin, mainly in southern
Europe, West Asia (Turkey), or a developing country. The pro-
portion of those visiting friends and relatives among all travelers
developing hepatitis A increased from 15.5% in 1988–1993 to
28.2% in 2000–2004. Infections in those visiting friends and
relatives were predominantly observed in those 0–14 years old,
whereas overall, most patients were 15–29 years old.
HAV infection was diagnosed mainly during summer and
autumn for both autochthonous and imported infections. A
second peak in spring was detected for travelers after stays in
Southeast Asia and at Caribbean destinations. Additionally, re-
port of exposure to an infected contact as outcome variable
was associated with absence of travel history (OR, 2.60; 95%
CI, 2.25–3.02) independently by logistic regression analyses.
For patients with HAV infection with travel history as de-
pendent variable, logistic regression analyses identified younger
age (OR, 1.04; 95% CI, 1.01–1.07), foreign nationality (OR,
3.58; 95% CI, 2.88–4.45), reported exposure to contaminated
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Table 1. Demographic characteristics and travel histories for hepatitis A virus (HAV)–infected
subjects ( ).np 6592
Factor
No. (%) of subjects
Pa
All cases,
1988–2004
Travel-related cases
1988–1993 1994–1999 2000–2004
Imported from abroad 2784 (42.2) 1420 (39.9) 991 (46.7) 373 (41.2)
Exposure in Switzerland 2631 (39.9) … … …
Unknown 1177 (17.9) … … …
Reported exposure riskb
Injectable drug use 1033 (39.3) 70 (4.9) 10 (1.0) 0
Sexual contact 79 (3.0) 9 (0.6) 21 (2.1) 4 (1.1)
Contact with patient infected with HAV 880 (33.4) 147 (10.4) 157 (15.8) 27 (7.2)
Contaminated food or water 114 (4.3) 58 (4.1) 92 (9.3) 141 (37.8)
Blood transfusion 7 (0.3) 4 (0.3) 1 (0.1) 0
Health profession 36 (1.4) 19 (1.3) 14 (1.4) 0
Other 54 (2.1) 19 (1.3) 31 (3.1) 14 (3.8)
Unknown 428 (16.3) 1094 (77.0) 665 (67.1) 187 (50.1)
Sex
Female 2424 (36.8) 523 (36.8) 390 (39.4) 147 (39.4) NS
Male 4148 (62.9) 893 (62.9) 597 (60.2) 224 (60.1) Referent
Not available 20 (0.3) 4 (0.3) 4 (0.4) 2 (0.5)
Age group, years
0–14 1164 (17.7) 195 (13.7) 283 (28.6) 129 (34.6) !.001
15–29 2647 (40.2) 581 (40.9) 229 (23.1) 79 (21.2) !.001
30–44 1633 (24.8) 392 (27.6) 278 (28.1) 91 (24.4) Referent
45–59 763 (11.6) 182 (12.8) 149 (15.0) 57 (15.3) NS
160 352 (5.3) 57 (4.0) 50 (5.0) 17 (4.6) NS
Unknown 33 (0.5) 13 (0.9) 2 (0.2) 0
Nationality
Swiss 4339 (65.8) 889 (62.6) 531 (53.6) 198 (53.1) Referent
Foreign 1179 (17.9) 296 (20.8) 288 (29.1) 117 (31.4) !.001
Unknown 1074 (16.3) 235 (16.5) 172 (17.4) 58 (15.5)
History of travel
Africa 568 (20.4) 315 (22.2) 167 (16.9) 86 (23.1)
Latin America/Caribbean 402 (14.4) 213 (15.0) 129 (13.0) 60 (16.1)
Asia 560 (20.1) 284 (20.0) 197 (19.9) 79 (21.2)
Europe/North America 1033 (37.1) 489 (34.4) 426 (43.0) 118 (31.6)
Australia/Pacific 15 (0.5) 4 (0.3) 9 (0.9) 2 (0.5)
Unknown 206 (7.4) 115 (8.1) 63 (6.4) 28 (7.5)
Season of onsetc
Winter (January–March) 1533 (23.3) 349 (24.6) 190 (19.2) 54 (14.5)
Spring (April–June) 1075 (16.3) 276 (19.4) 134 (13.5) 56 (15.0)
Summer (July–September) 1396 (21.2) 352 (24.8) 282 (28.5) 97 (26.0)
Autumn (October–December) 1677 (25.4) 369 (26.0) 201 (20.3) 99 (26.5)
Unknown 911 (13.8) 74 (5.2) 184 (18.6) 67 (18.0)
Course of disease
Hospitalization 1424 (21.6) 237 (16.7) 197 (19.9) 100 (26.8)
No hospitalization 2907 (44.1) 766 (53.9) 529 (53.4) 1 (0.3)
Unknown 2261 (34.3) 417 (29.4) 265 (26.7) 272 (72.9)
NOTE. was considered statistically significant. NS, not significant.P ! .05
a Nonparametric test for trend developed by Cuzick [10], an extension of the Wilcoxon rank sum test.
b In decreasing order of exclusion; in the “all cases” column, data are for the cases acquired in Switzerland.
c Reported as date of diagnosis or date of manifestation.
food (OR, 2.42; 95% CI, 1.73–3.38), reported exposure to an
infected contact (OR, 0.46; 95% CI, 0.37–0.56), and manifes-
tation or diagnosis of HAV infection in summer (OR, 1.60;
95% CI, 1.34–1.92) as independently associated factors.
Hospitalization was indicated in 19.2% of imported HAV in-
fections, compared with 21.8% of cases of hepatitis A acquired
in Switzerland ( ). No fatalities due to hepatitis A wereP ! .001
recorded that were clearly associated with travel and were not
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Figure 1. Incidences of hepatitis A virus infections in selected frequently visited countries, 1988–2004. Incidences for the years 2000–2004 (per
100,000 person-months of travel): Brazil, 7.5; Egypt, 10.9; India, 12.3; Kenya, 12.0; Mexico, 6.2; Thailand, 3.0; and Turkey, 14.1.
attributed to any concomitant condition. The proportion of pa-
tients aged 50 years was 11.3% and 11.9% for HAV infections
acquired in Switzerland and abroad, respectively.
Both the absolute number of travel-associated HAV cases
and the attack rates among international travelers to destina-
tions of high or intermediate risk of transmission declined over
the study period (table 2). Travel within Europe or to North
America is currently associated with a crude attack rate of !1.0
cases per 100,000 travelers. An intermediate attack rate of 1.0–
4.0 cases per 100,000 travelers was found for travelers to various
destinations in Asia, the Caribbean, or Central America. For
African destinations (excluding South Africa), South America,
and the Indian subcontinent, crude attack rates exceeded 4.0
cases per 100,000 travelers. The corresponding incidences per
month among nonimmune subjects varied between 6.0 and
30.0 cases per 100,000 travelers, with highest rates found for
Africa, south-central Asia (mainly the Indian subcontinent),
and Latin America. Figure 1 shows selected country-specific
data. As shown in table 3, the estimated immunization-attrib-
uted reduction in incidence showed a region-specific distri-
bution and varied between 35.0% and 61.8%.
DISCUSSION
The actual overall attack rates of HAV infections among trav-
elers outside industrialized countries ranged between 1.0 and
7.0 cases per 100,000 travelers. The corresponding incidences
for nonimmune travelers varied between 6.0 and 30.0 cases per
100,000 months of stay in virtually all developing countries.
That is 10 to 50 times lower than the 300 cases per 100,000
reported 2 decades ago [1, 4]. Obviously, this decrease mirrors
mainly improved sanitary conditions, at least where travelers
usually consume food and beverages. For the destination Mex-
ico, an incidence of 6.2 cases per 100,000 person-months was
registered in the period 2000–2004. Because hardly any travelers
from Switzerland visit friends and relatives in this country, this
documents the risk for tourists and business travelers. The
monthly incidence was particularly high for travelers to Latin
America and was significantly higher than for travelers to
Southeast Asia ( ). Similar incidences were found forPp .009
British [11] and Canadian travelers (33 cases per 100,000 per-
son-months of travel [3, 12].
Southern Europe no longer is a high-risk destination, com-
pared with other parts of Europe, whereas travel to more remote
parts of eastern Europe is clearly associated with the risk of
acquiring HAV infection [13]. An Italian case-control study
[14] found that the risk increased by a factor of 3 for travelers
to southern or eastern Europe, compared with no travel. Pop-
ular tourist destinations in North Africa (e.g., Egypt, Morocco,
and Tunisia) or West Asia (e.g., Turkey), often chosen for short-
term visits, clearly are regions with high risk. This stands in
contrast to the official US source that lists Turkey as country
with intermediate risk only [15]. Short-term visitors are of
special concern, because they are often frequent travelers with
a cumulative exposure to HAV [1]. Stays in luxury hotels by
no means are exempt from risk [12]; this has recently been
demonstrated by an outbreak ( ) among mainlynp 352
German tourists who had stayed in a first-class hotel in Hur-
ghada, Egypt [16]. Conflicts in a particular region result in
destruction of infrastructure and a decline in sanitary condi-
tions. The transient increase in the HAV attack rates among
Swiss travelers to former Yugoslavia between 1994 and 1999
illustrates this.
The proportion of travel-associated cases among all reported
HAV infections varies greatly between countries. This may de-
pend in part on the data source. For Switzerland, the average
proportion of all imported infections (42%) and of infections
associated with stays exclusively in high- or intermediate-risk
countries for HAV (27%) are similar to or higher than data
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Table 3. Estimated reduction in incidence among travelers through immunity against hepatitis A virus (HAV).
Selected region
Reduction in
incidence, %
Monthly incidence
per 100,000
extrapolated from
prevaccination era
to 2000–2004a
Total
monthly incidence
per 100,000,
2000–2004b
Regions with high to intermediate risk for HAV 35.0 10.0 6.5
South America 52.2 18.0 8.6
North Africa 48.0 20.0 10.4
Sub-Saharan Africa 61.8 22.0 8.4
South-central Asia 58.8 25.0 10.3
a The trend before 2000–2004 was evaluated by using the incidences of HAV infection before widespread vaccine use (1971–1993).
This represents a surrogate of effects other than vaccination (e.g., improvements of sanitary conditions at destination).
b Data are from table 2.
from European and North American studies published after
1990: 25% (United Kingdom) [17], 28% (Italy) [14], up to
one-third (Canada) [12, 18], and 32.6% to 150% (Germany)
[19, 20]. The very low proportion of 4%–6% registered in the
United States thus far [21] may illustrate that exposure risk
data were assessed differently with respect to the order of ex-
clusion of the travel history.
Travel-associated HAV infections differed with nationality
and age of the patients. Foreign nationals (25.2%) were slightly
overrepresented compared with the foreigners among Swiss res-
idents (20%). The majority of foreigners were classified as mi-
grants or persons visiting friends and relatives, and this pro-
portion increased during the study period. Adults likely to be
immune because of previous exposure to HAV ask less fre-
quently for pretravel health advice before traveling with their
nonimmune Swiss-born children to their high-risk countries
of origin. Often they visit areas outside usual tourist routes and
have a longer duration of stay, including closer contacts to the
local population [22–24]. As shown by the multivariate analysis,
the patients who had traveled to visit friends or relatives were
younger than those with HAV acquired in Switzerland; their
infections occurred more often in the summer months, the
usual vacation time of those visiting friends and relatives; and
exposure to contaminated food was less frequently reported
(data not shown), which may indicate a decreased awareness
of exposure risks. Therefore, special attention is needed to reach
those traveling to visit friends and relatives for pretravel health
advice. In contrast, senior travelers (50 years; 11.9%) were
rather underrepresented, because 19% of Swiss travelers belong
to this age group; this anomaly may be explained by higher
levels of previously naturally acquired immunity or by safer
patterns of behavior [4, 25].
The spread of imported HAV infections from children to
household contacts, to other children, and to professionals in
schools or day care centers has been previously described [26–
29]. Transmission of imported hepatitis A by food handlers has
been described in Switzerland [30] and elsewhere [31].
The validity of the data is linked to the reliability of the
databases used. Because both laboratory and physicians are
required to report diagnosed cases of HAV infection indepen-
dently, the sensitivity of the surveillance system is considered
to be high (∼80%). The proportion of cases with missing phy-
sician-based information has decreased from 29.3% in 1988 to
8.6% in the past 2 years. Additional sources of underreporting
may be asymptomatic infection or cases diagnosed and treated
abroad. Thus, the attack rates and incidences are rather un-
derestimated. Given the fact that annual travelers’ statistics are
usually based on national information, they represent rough
estimates that gain more robustness through the classification
into regions. Pretravel medical advice was used as a surrogate
to estimate immunity against HAV, because we were missing
recent serological data about immunization coverage among
travelers. With regard to validity, the resulting incidences for
nonimmune subjects and those for nonimmune subjects, ex-
trapolated from the prevaccination era, show consistency.
When hepatitis A vaccination [32, 33] was introduced in
Switzerland early in 1992, it was recommended for risk groups
only. This strategy was only partially effective, because many
travelers, mainly those visiting friends or relatives or those to
popular tourist destination close by (across the Mediterranean
for Europeans, Mexico for US and Canadian travelers), often
fail to seek travel health advice. Despite considerable reductions
in incidence attributed to the impact of HAV vaccination and
despite decreasing population-based HAV seroprevalence at
many destinations [34, 35], there is still potential for improve-
ment. We should focus on the risk perceptions of travelers,
such as those visiting friends and relatives and those going to
popular destinations. Thus, through addressing hepatitis A risk
among those visiting friends and relatives, we would not only
protect individuals but may also potentially disrupt the trans-
mission cycle in communities abroad and back home [22, 36].
Targeted routine HAV vaccination of at-risk groups could be
effective, as was shown with HAV vaccination of children of
Turkish and Moroccan origin in Amsterdam [37]. Further stud-
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ies are needed to assess the traveler-based lifetime risk of ex-
posure to HAV and to evaluate in more depth the impact of
different vaccination strategies considering travelers from coun-
tries with very low HAV endemicity [36, 38, 39].
The number of HAV infections decreased substantially over
the past 2 decades for imported cases as well as for infections
acquired in Switzerland. This is only partly the result of HAV
vaccination. Nonimmune travelers still have an incidence of
6.0–30.0 per 100,000 person-months at risk destinations. The
risk at nearby destinations, such as Mexico for Americans or
Turkey and North Africa for Europeans, is often underesti-
mated. Two strategic options for prevention of HAV infection
need to be considered: (1) targeting tourists unaware of risk
of HAV infections at close destinations and those visiting friends
and relatives, and (2) universal hepatitis A immunization. In
populations with a high proportion of lifetime HAV exposure,
the latter may be appropriate.
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